Chiesi Limited has announced today that it will no longer be supplying Vertab® (verapamil hydrochloride) SR 240mg tablets in the UK. The decision to discontinue verapamil hydrochloride has been made due to challenges in continuity of supply across the UK. As a result, Chiesi has concluded that ceasing production will allow efforts to be redirected towards newer, more viable alternatives.
Chiesi ceased supplying verapamil hydrochloride on 27th April 2021, with remaining supplies continuing to be sold throughout the year. Discontinuation notices will be issued to usual contact points during June 2021.
Although the decision to cease production of verapamil hydrochloride is regrettable, Chiesi remains committed to delivering better care and quality of life for people living with hypertension and angina. The cardiovascular therapeutic area continues to be a primary focus in Chiesi’s research and development pipeline, and the production and commercialisation of innovative medicines remains its priority.